TCTR20181220006尚未招募1 期
Bioequivalence evaluation of test and reference formulations of Voriconazole 200 mg tablets administered to 38 healthy volunteers after single dose (2-Period, 2-Treatment, 2-Sequence, 2-Way, Crossover Study under fasting condition)
Bio-innova and Synchron.Co.,Ltd0 个研究点目标入组 38 人开始时间: 2018年12月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Willingness to provide written informed consent prior to participate in the study.
- •2.Healthy Thai subjects are between 18 to 55 years of age.
- •3.The Body Mass Index (BMI) ranges from 18.5 to 30 kg/m2.
- •4.Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 7 mL of blood for monitoring subjects’ safety after the completion of the study.
- •5.Negative urine pregnancy test for women and no breast-feeding.
- •6.Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician.
排除标准
- •1.History or evidence of allergy or hypersensitivity to Voriconazole or any related drugs or any of the excipients of this product.
- •2.Subject with B.P. is Systolic B.P < 90, ≥140 mm/Hg, Diastolic B.P < 60, ≥90 mm/Hg or pulse rate > 100 beats per minute.
- •3.Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).*
- •4.Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR).*
- •5.Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).*
- •6.Positive of hepatitis B or C virus.
- •7.12-lead ECG demonstrating QTc >450 msec, a QRSD >120 msec or with an abnormality considered clinically significant at Screening. If QTc exceeds 450 msec, or QRSD exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc or QRSD values should be used to determine the subject’s eligibility*.
- •8.History or evidence of heart, renal, hepatic disease, pulmonary obstructive disease, bronchial asthma, hypertension, glaucoma.
- •9.History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy.
- •10.Any major illness in the past 3 months or any significant ongoing chronic medical illness.
- •11.History of psychiatric disorder.
- •12.History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
- •13.History of usually smoking (more than 10 cigarettes per day), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of the study.
- •14.High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
- •15.Positive drug abused test in urine (Benzodiazepines, Marijuana (THC), Amphetamine, Cocaine and Opioids).
- •16.Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-Provera® must be discontinued at least 6 months) prior to receiving the first dose of study medication.
- •17.History of difficulty in accessibility of veins in left and right arm.
- •18.Blood donation (one unit or 450 mL) within the past 3 months before the study.
- •19.Participation in any clinical study within the past 3 months before the study.
- •20.Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol.
- •21.Difficulty in swallowing capsules and/or tablets.
- •(* Depend on decision of principal investigator and/or clinical investigator)
研究者
相似试验
已完成
4 期
To evaluate in Human volunteers bioequivalence of Clobetz Cream (Clobetasol propionate USP 0.05% w/w)with Reference Listed Drug Tenovate Cream (Clobetasol propionate BP 0.05% w/w) , by comparison of vaso constriction caused.CTRI/2012/08/002893Apex Laboratories Pvt30
已完成
4 期
To evaluate in Human volunteers bioequivalence of Flutisone Cream (Fluticasone propionate BP 0.05% w/w)with Reference Listed Drug Flutivate Skin Cream (Fluticasone propionate IP 0.05% w/w) , by comparison of vaso constriction caused.CTRI/2012/08/002881Apex Laboratories Pvt Ltd30
已完成
4 期
To evaluate in Human volunteers bioequivalence of Motyvate Cream with Reference Listed Drug Elocon Cream , by comparison of vaso constriction caused.CTRI/2013/01/003275Apex Laboratories Pvt Ltd30
招募中
不适用
Bioequivalency study of two different Metformin formulationsIRCT20111107008022N7Reihaneh Pharmaceutical Company24
尚未招募
Unknown
Bioequivalence study of two different Ciprofloxacin formulationsIRCT20111107008022N13Zagrous Darou Pharmaceutical Company24